Literature DB >> 16369985

Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.

Mirjam J A Engelen1, Henrike E Kos, Pax H B Willemse, Jan G Aalders, Elisabeth G E de Vries, Michael Schaapveld, Renee Otter, Ate G J van der Zee.   

Abstract

BACKGROUND: Consultant gynecologic oncologists from the regional Comprehensive Cancer Center assisted community gynecologists in the surgical treatment of patients with ovarian carcinoma when they were invited. For this report, the authors evaluated the effects of primary surgery by a gynecologic oncologist on treatment outcome.
METHODS: The hospital files from 680 patients with epithelial ovarian carcinoma who were diagnosed between 1994 and 1997 in the northern part of the Netherlands were abstracted. Treatment results were analyzed according to the operating physician's education by using survival curves and univariate and multivariate Cox regression analyses.
RESULTS: Primary surgery was performed on 184 patients by gynecologic oncologists, and on 328 patients by general gynecologists. Gynecologic oncologists followed surgical guidelines more strictly compared with general gynecologists (patients with International Federation of Gynecology and Obstetrics [FIGO] Stage I-II disease, 55% vs. 33% [P=0.01]; patients with FIGO Stage III disease, 60% vs. 40% [P=0.003]) and more often removed all macroscopic tumor in patients with FIGO Stage III disease (24% vs. 12%; P=0.02). When patients were stratified according to FIGO stage, the 5-year overall survival rate was 86% versus 70% (P=0.03) for patients with Stage I-II disease and 21% versus 13% (P=0.02) for patients with Stage III-IV disease who underwent surgery by gynecologic oncologists and general gynecologists, respectively. The hazards ratio for patients who underwent surgery by gynecologic oncologists was 0.79 (95% confidence interval [95%CI], 0.61-1.03; adjusted for patient age, disease stage, type of hospital, and chemotherapy); when patients age 75 years and older were excluded, the hazards ratio fell to 0.71 (95% CI, 0.54-0.94) in multivariate analysis.
CONCLUSIONS: The surgical treatment of patients with ovarian carcinoma by gynecologic oncologists occurred more often according to surgical guidelines, tumor removal more often was complete, and survival was improved. Copyright (c) 2005 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 16369985     DOI: 10.1002/cncr.21616

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  51 in total

1.  Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

Authors:  Teresa Granato; Cecilia Midulla; Flavia Longo; Barbara Colaprisca; Luigi Frati; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-04-13

2.  An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers.

Authors:  Zhen Zhang
Journal:  Rev Obstet Gynecol       Date:  2012

3.  Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; Moune Jabre-Raughley; Amy K Brown; Katina M Robison; M Craig Miller; W Jeffery Allard; Robert J Kurman; Robert C Bast; Steven J Skates
Journal:  Am J Obstet Gynecol       Date:  2010-05-14       Impact factor: 8.661

4.  Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia.

Authors:  Swantje Piszczan; Dawit Desalegn; Hezkiel Petros; Mengistu Gurmu; Eric Sven Kroeber; Adamu Addissie; Rafael Mikolajczyk; Rahel G Ghebre; Assefa Mathewos; Christoph Thomssen; Ahmedin Jemal; Eva Johanna Kantelhardt
Journal:  Oncologist       Date:  2019-04-25

5.  Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.

Authors:  Jaume Capellades; Josep Puig; Sira Domenech; Teresa Pujol; Laura Oleaga; Angels Camins; Carles Majós; Rocio Diaz; Christian de Quintana; Pilar Teixidor; Gerard Conesa; Gerard Plans; Josep Gonzalez; Natalia García-Balañà; Jose Maria Velarde; Carmen Balaña
Journal:  J Neurooncol       Date:  2017-12-28       Impact factor: 4.130

6.  [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors].

Authors:  Shi-Peng Gong; Yong-Ning Chen; Ya-di Zhang; Wei Yao; Li Chen; Shi-San Liu; Huan Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

7.  In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.

Authors:  Lele Shashikant; P Kesterson Joshua
Journal:  J Obstet Gynaecol India       Date:  2009 May-Jun

8.  HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.

Authors:  Blanca Ortiz-Muñoz; Eduardo Aznar-Oroval; Ana García García; Amparo Covisa Peris; Pilar Perez Ballestero; Marina Sanchez Yepes; Tomás Garcia Lozano; Carmen Illueca Ballester; Enrique García Garcia
Journal:  Tumour Biol       Date:  2014-04-27

9.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

10.  Advanced ovarian cancer: what should be the standard of care?

Authors:  Barbara A Goff
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.